RxDoctor Payments Data

Rajendra Patel, MD

Interventional Cardiology · New York, NYNPI 1649357633

Payments from drug & device makers

$7,070in general payments, 2019–2025

Across 45 payments — averaging $157.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vioptix Inc$6K
  • AstraZeneca$230
  • Novo Nordisk$131
  • Abbott$126
  • Abiomed$123
  • Cvrx, Inc.$91
  • plus $369 from 16 others

What the payments were for

  • Consulting fees$6,00085%
  • Food & beverage$96114%
  • Education$1092%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,070 in reported general payments places this provider in the 40th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$363,461
Medicare patients
562
Services billed
2,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate231$238,262
EliquisApixaban200$202,810
TrulicityDulaglutide82$128,554
OzempicSemaglutide103$112,354
TradjentaLinagliptin114$100,173
JardianceEmpagliflozin92$87,305
Diclofenac Sodium244$81,539
XareltoRivaroxaban55$50,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$45,743
EntrestoSacubitril/Valsartan37$39,863
ProliaDenosumab19$31,576
JanumetSitagliptin Phos/Metformin Hcl35$26,807
MounjaroTirzepatide22$26,487
LinzessLinaclotide36$26,316
CreonLipase/Protease/Amylase26$18,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$59$282,707292 claims
PfizerEliquis$27$202,810200 claims
Lilly USA, LLCTrulicity, Mounjaro$17$155,041104 claims
Novo NordiskOzempic, Rybelsus$131$125,329116 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$17$66,107126 claims
AbbVieLinzess, Creon$21$45,23662 claims
AmgenProlia$14$31,57619 claims
AstraZenecaBrilinta, Farxiga$230$31,26133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →